Lenvatinib

Where the papers sit

32 papers from the last 6 months study lenvatinib directly · updated from PubMed 11 Oct 2026

• Immunotherapy in Liver Cancer

  Lenvatinib is increasingly being combined with PD-1 or PD-L1 blockade and locoregional therapy for unresectable hepatocellular carcinoma. Trials test nivolumab, sintilimab, durvalumab–tremelimumab or atezolizumab-based sequencing, with progression-free survival, objective response and conversion to surgery as recurring endpoints. Hepatic arterial infusion chemotherapy and transarterial embolization are being added to intensify responses, but optimal timing of immune therapy remains unsettled. Real-world studies emphasize dose intensity, safety and treatment selection after prior checkpoint inhibition.

  14 papers · 43.8%

• Advanced Renal Cell Carcinoma

  Pembrolizumab–lenvatinib is being positioned as a major first-line option for advanced renal cell carcinoma, with CLEAR analyses extending benefit across subgroups. Real-world comparisons weigh this regimen against nivolumab–cabozantinib and cabozantinib-based therapy using survival, safety and prognostic factors. Belzutifan–lenvatinib is emerging after prior treatment, while Bayesian and cost-effectiveness analyses refine treatment selection. The evidence is moving toward individualized sequencing rather than a single preferred combination.

  9 papers · 28.1%

• Resistance Mechanisms in HCC

  Lenvatinib resistance in hepatocellular carcinoma is being traced to adaptive redox control, epithelial–mesenchymal transition and focal-adhesion signaling. EGR1–ZNF768–SLC7A11 responses limit ferroptosis, while RPRD1A–ITGA5–FAK signaling and NDST2-mediated EGFR N-glycosylation sustain resistance. Combination strategies, including ADI-PEG 20, immune therapy and biomimetic nanoplatforms, aim to restore sensitivity or improve delivery. The work is moving toward mechanism-guided sensitization rather than empiric escalation alone.

  9 papers · 28.1%